Cervical cancer still poses a significant global challenge. Developed countries have
mitigated this challenge by the introduction of structured screening programmes and, more …

Viral infections contribute as a cause of 15–20% of all human cancers. Infection by
oncogenic viruses can promote different stages of carcinogenesis. Among many types of …

Introducing HPV Vaccine in Developing Countries — Key Challenges and Issues | New England
Journal of Medicine Skip to main content The New England Journal of Medicine homepage …

Abstract The American Cancer Society (ACS) has developed guidelines for the use of the
prophylactic human papillomavirus (HPV) vaccine for the prevention of cervical …

The Human Papillomavirus (HPV) vaccines have been widely introduced in the national
immunization programs in most of the medium and high income countries following …

The worldwide prevalence of infection with human papillomavirus (HPV) in women without
cervical abnormalities is 11–12% with higher rates in sub-Saharan Africa (24%), Eastern …

This report summarizes the epidemiology of human papillomavirus (HPV) and associated
diseases, describes the licensed HPV vaccines, provides updated data from clinical trials …

Although available human papillomavirus (HPV) vaccines have high efficacy against
incident infection and disease caused by HPV types that they specifically target, new …

Candidate prophylactic vaccines based on papillomavirus L1 virus-like particles (VLPs) are
currently in human clinical trials. The main long-term goal of the vaccine is to reduce the …

The availability of both human papillomavirus (HPV) vaccination and alternative screening
tests has greatly improved the prospects of cervical cancer prevention in sub-Saharan …